Search

The development of digital pedagogy in early childhood education and care (ECEC) is a relevant issue. The role of the ECEC leader in initiating and leading the development of digital pedagogy is important. The aim of this study was to explore the views of ECEC leaders on digital pedagogy and its development, as little research has been done on the subject. The data was collected in the context of continuing professional development for ECEC leaders in Finland. The data consists of 39 development plans that were drawn up by the participants and it was analyzed using qualitative content analysis. The research indicates that ECEC leaders hold diverse perspectives on digital pedagogy but acknowledge the significance of leadership in fostering staff digital skills, formulating a shared strategy, and involving children and the community. The findings suggest that digital pedagogy should be an inherent component of the fundamental mission of ECEC, which centers around play-based learning. The concept of play-based digital pedagogy (PBDP) is proposed as a framework for digital learning in ECEC.

Abstract Background To be eligible to receive treatment with an anti-tumour necrosis factor (TNF), non-radiographic axial spondyloarthritis (nr-axSpA) patients require either elevated levels of C-reactive protein (CRP) (CRP > upper limit of normal (ULN)) or magnetic resonance imaging assessment showing inflammation of the sacroiliac joints, in addition to meeting criteria for high disease activity. Many axSpA patients are classified as ‘CRP-negative’, or CRP normal, despite having levels close to the ULN, and are therefore formally ineligible for treatment. The aim of this study was to investigate the likelihood of a CRP test indicating elevated levels in axSpA patients that have previously tested CRP normal. Methods RAPID-axSpA (NCT01087762) enrolled patients who were either magnetic resonance imaging positive or had elevated CRP (> ULN: 7.9 mg/L). CRP data from the double-blind period for placebo-randomised patients until re-randomisation to certolizumab pegol (week 16 for ASAS20 non-responders/week 24 for ASAS20 responders) were analysed. CRP was assessed at screening, baseline, and nine time points to week 24. Linear mixed models were used to investigate time trends, variability, and correlations of CRP data. Results Of 106 placebo-randomised patients with baseline CRP assessments, 26 (25%) tested CRP normal at baseline, of whom 13 (50%) had ≥ 1 test indicating elevated CRP to week 16. Of 80/106 (75%) patients with elevated baseline CRP, 25 (31%) had ≥ 1 normal CRP test to week 16. Linear mixed models did not reveal changes in mean CRP across placebo patients from baseline to week 24. Conclusions In axSpA patients with CRP